Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ana G. Lujan Hernandez"'
Autor:
Linya Wang, Pankaj Garg, Kara Y. Chan, Tom Z. Yuan, Ana G. Lujan Hernandez, Zhen Han, Sean M. Peterson, Emily Tuscano, Crystal Safavi, Eric Kwan, Mouna Villalta, Melina Mathur, Joyce Lai, Fumiko Axelrod, Colby A. Souders, Chloe Emery, Aaron K. Sato
Publikováno v:
PLoS ONE, Vol 19, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/19d9881e92ee441db2ab1b748136eaae
Autor:
Tom Z. Yuan, Pankaj Garg, Linya Wang, Jordan R. Willis, Eric Kwan, Ana G Lujan Hernandez, Emily Tuscano, Emily N. Sever, Erica Keane, Cinque Soto, Eric M. Mucker, Mallorie E. Fouch, Edgar Davidson, Benjamin J. Doranz, Shweta Kailasan, M. Javad Aman, Haoyang Li, Jay W. Hooper, Erica Ollmann Saphire, James E. Crowe, Qiang Liu, Fumiko Axelrod, Aaron K. Sato
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Coronavirus disease 2019 (COVID-19) is an evolving global public health crisis in need of therapeutic options. Passive immunization of monoclonal antibodies (mAbs) represents a promising therapeutic strategy capable of conferring immediate protection
Externí odkaz:
https://doaj.org/article/b6c1901170674ee7807acd867a09110b
Autor:
Qiang Liu, Pankaj Garg, Burcu Hasdemir, Linya Wang, Emily Tuscano, Emily Sever, Erica Keane, Ana G Lujan Hernandez, Tom Z. Yuan, Eric Kwan, Joyce Lai, Greg Szot, Sreenivasan Paruthiyil, Fumiko Axelrod, Aaron K. Sato
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
G protein-coupled receptors (GPCRs) are a group of seven-transmembrane receptor proteins that have proven to be successful drug targets. Antibodies are becoming an increasingly promising modality to target these receptors due to their unique properti
Externí odkaz:
https://doaj.org/article/4eac4f5c52cc4fb2ab2059e4e0a65757
Autor:
Tom Z. Yuan, Carolina Lucas, Valter S. Monteiro, Akiko Iwasaki, Marisa L. Yang, Hector F. Nepita, Ana G. Lujan Hernandez, Joseph M. Taft, Lester Frei, Sai T. Reddy, Cédric R. Weber, Kevin P. Malobisky, Rodrigo Mesquita, Aaron K. Sato
Bispecific antibodies have emerged as a promising strategy for curtailing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report highlights RBT-0813 (also known as TB493-04), a synthetic, humanized, receptor-bin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3190ce9f07e85b900b58fa0c94cd80e5
https://doi.org/10.1101/2022.01.04.474803
https://doi.org/10.1101/2022.01.04.474803
Autor:
Tom Z. Yuan, Pankaj Garg, Linya Wang, Jordan R. Willis, Eric Kwan, Ana G Lujan Hernandez, Emily Tuscano, Emily N. Sever, Erica Keane, Cinque Soto, Eric M. Mucker, Mallorie E. Fouch, Edgar Davidson, Benjamin J. Doranz, Shweta Kailasan, M. Javad Aman, Haoyang Li, Jay W. Hooper, Erica Ollmann Saphire, James E. Crowe, Qiang Liu, Fumiko Axelrod, Aaron K. Sato
Publikováno v:
mAbs
article-version (VoR) Version of Record
mAbs, Vol 14, Iss 1 (2022)
article-version (VoR) Version of Record
mAbs, Vol 14, Iss 1 (2022)
Coronavirus disease 2019 (COVID-19) is an evolving global public health crisis in need of therapeutic options. Passive immunization of monoclonal antibodies (mAbs) represents a promising therapeutic strategy capable of conferring immediate protection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01454b5bcdde59a32f20af4ed44d29d1
http://europepmc.org/articles/PMC8726723
http://europepmc.org/articles/PMC8726723
Autor:
Yanan Lu, Timothy C. Germann, Adrian Enriquez, Ruben Diaz Avalos, Marit J. van Gils, Ana G. Lujan Hernandez, Yoann Aldon, Guojun Lang, Mohammad M. Sajadi, Elizabeth Feeney, John Ingraham, Georgia D. Tomaras, Milite Abraha, Junli Liu, Jacob Glanville, S. Moses Dennison, Minsoo Kim, Erica Ollmann Saphire, Sawsan Youssef, Ross S. Federman, Gillian Q. Horn, Bingqing Shen, Sean Hui, Anne L. Palser, Joseph M. Fernandez, Gevorg Grigoryan, Vamseedhar Rayaprolu, David D. Ho, Jieyun Yin, Sharon L. Schendel, Jian Yu, Haoyang Li, Shelly J. Krebs, Qian Zhang, Ronald R. Cobb, Colin Mann, Eduardo Olmedillas, Rogier W. Sanders, Robin Green, Hyeong Mi Kim, Tierra Buck, Dawid Zyla, Hanif Ali, Paul Kellam, Terence H. Rabbitts, Diptiben V. Parekh, Anna J. MacCamy, Cheolmin Kim, Kuan-Ying A. Huang, Milan T. Tomic, Andrew T. McGuire, Tom Z. Yuan, Chitra Hariharan, Zahra Rikhtegaran Tehrani, Bjoern Peters, Xiaoying Yu, Sooyoung Lee, CoVIC-DB team, Kan Li, Leonidas Stamatatos, Cheuk Lun Leung, Chao Kong, Michelle Zandonatti, Fei Lan, Yongcong Tan, Aaron K. Sato, Kathryn M. Hastie, Liang Schweizer, Sanja Aracic, Jonne L. Snitselaar, Weidong Jiang, Kelly Shaffer, Jimin Seo, Daniel Bedinger
Publikováno v:
Science, 374(6566), 478-472. American Association for the Advancement of Science
Science
Science
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d77d508652c2afc125beaacf08e3394
https://pure.amc.nl/en/publications/defining-variantresistant-epitopes-targeted-by-sarscov2-antibodies(74d2b427-bf9c-4668-a36e-35475cd84986).html
https://pure.amc.nl/en/publications/defining-variantresistant-epitopes-targeted-by-sarscov2-antibodies(74d2b427-bf9c-4668-a36e-35475cd84986).html
Autor:
Tom Z. Yuan, Mohammad Javad Aman, Fumiko Takada Axelrod, Erica Keane, Aaron K. Sato, Yasmina N Abdiche, Madeleine Noonan-Shueh, Qiang Liu, Shweta Kailasan, Ana G Lujan Hernandez
Publikováno v:
Antibody Therapeutics
Background Development of successful neutralizing antibodies is dependent upon broad epitope coverage to increase the likelihood of achieving therapeutic function. Recent advances in synthetic biology have allowed us to conduct an epitope binning stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa1b7602025d45b02896477579bd85bf
https://pubmed.ncbi.nlm.nih.gov/33912793
https://pubmed.ncbi.nlm.nih.gov/33912793